undamentalytics Newsletter
Sign in

Beta Bionics, Inc. (BBNX) stock

Add to watchlist

Add holding +

NASDAQ: BBNX Nasdaq Health Care Equipment Next results ~January 13, 2027

D Fundamentals grade

Beta Bionics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$4.6

Valuation models combined (3)

Base case. Range ~$3.9–$5.0. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Beta Bionics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 8 selling0 purchases and 52 sales by directors and officers, last 12 monthsInsider trades
  • Funds81 adding, 58 cuttingOf 35 active managers that changed their stake, 14 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Beta Bionics files

Where Beta Bionics stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $127m, up 43.7% on a year earlier, slower than the 52.5% growth a quarter earlier. That growth ranks 3 of 58 among the health care equipment companies we cover. Free-cash-flow margin rose to -51.8% from -68.3% a year earlier. Operating margin widened to -72.7% from -77.4%. The diluted share count is up 44.6% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks. Our revenue-to-maturity cash-flow model value is $4.07 a share, against a share price of $18.05.

Source: 10-Q filed October 27, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 13, 2027 (estimated)

Beta Bionics, Inc.'s trailing-twelve-month revenue grew 43.7% year on year, with a free-cash-flow margin of -51.8%. Where it stands out: revenue growth of 43.7% ranks 16 of 129 health care equipment companies we cover. Where it lags: change in share count of 44.6% ranks 104 of 115 health care equipment companies we cover.

Current signal Revenue growth decelerating: TTM revenue growth slowed to 43.7% (-8.8pp vs the prior quarter), the 2nd consecutive quarterly slowdown.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 43.7% over the last 12 months, against a median of 9.1% for health care equipment companies we cover.
  • Margins widening. Operating margin is up 4.7 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.1bn.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Growth slowing. The growth rate is 8.8 points lower than a quarter earlier.
  • Loss-making. Operating margin is -72.7%: costs exceed revenue.
  • Burning cash. Free cash flow was -51.8% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 18.4% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 44.6% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 83% and a beta of 1.3 against the S&P 500.

Latest results: FY2026 Q3

Filed October 27, 2026
Earnings per share
-$0.38 against an average estimate of -$0.51: beat by 26.6%
Revenue
$36m, up 30.3% on a year earlier
Share reaction
-13.0% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
Guidance given
estimated total revenue $124m to $126m (full year 2026); estimated percentage of new patient starts reimbursed through the PBP channel 37% to 39% (full year 2026)
Next report
October 27, 2026; average EPS estimate -$0.42

Beta Bionics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-5.1%
  • 1 week-22.5%
  • 1 month-16.1%
  • This year-47.8%
  • 1 year-41.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$127M
Operating margin
-72.7%
Net margin
-65.3%
EPS (TTM, diluted)
$-1.85

Growth

Revenue growth
+43.7%
Change in growth rate
−8.8 pts
Share count change
+44.6%

Cash

Free cash flow (TTM)
-$66M
FCF margin
-51.8%
Stock pay % of revenue
18.4%

Earnings

Last results
October 27, 2026
Next results (est.)
January 13, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Announcement
  4. Announcement
  5. Insider trade
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Beta Bionics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Beta Bionics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.5%: the 10-year Treasury yield (4.9%) plus a beta of 1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.0 ~$3.0–$6.8 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$4.2 ~$4.5–$16 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$3.9 ~$3.2–$4.7 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$4.6 ~$3.9–$5.0 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Beta Bionics, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2025Now
Share price$30.47$15.90
Market value$1.2bn$715m
+ Net debt (− = net cash)−$32m−$82m
Enterprise value$1.2bn$634m
Multiples
Price / sales 12.3x5.6x
Price / earnings ——
Price / free cash flow ——
EV / EBITDA ——

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.89 −37% $126m +25%
Next −$2.12 −12% $185m +48%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −8.5% on 90 days ago. In the last 30 days, 1 analyst raised Beta Bionics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Beta Bionics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.06 Current fiscal year, 60 days ago: −$1.90 Current fiscal year, 30 days ago: −$1.83 Current fiscal year, 7 days ago: −$1.88 Current fiscal year, Now: −$1.89 −$1.89 Next fiscal year, 90 days ago: −$2.34 Next fiscal year, 60 days ago: −$2.31 Next fiscal year, 30 days ago: −$2.33 Next fiscal year, 7 days ago: −$2.16 Next fiscal year, Now: −$2.12 −$2.12

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.06−$2.34
60 days ago −$1.90−$2.31
30 days ago −$1.83−$2.33
7 days ago −$1.88−$2.16
Now −$1.89−$2.12

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.51 −$0.38 +26.6%
Jun 2026 −$0.56 −$0.36 +35.1%
Mar 2026 −$0.45 −$0.36 +21.1%
Dec 2025 −$0.38 −$0.19 +49.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 27, 2026
  • Estimated total revenue full year 2026 $124m to $126m Raised
    “Estimated total revenue of approximately $124 million to $126 million (previously $121 million to $126 million).” source
  • Estimated gross margin full year 2026 58.5% to 59.5% Maintained
    “Estimated gross margin of 58.5% to 59.5% (no change versus previous guidance).” source
  • Estimated percentage of new patient starts reimbursed through the PBP channel full year 2026 37% to 39% Maintained
    “Estimated 37% to 39% of new patient starts reimbursed through the PBP channel (no change versus previous guidance).” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

15 analysts, Oct 2026
Buy1173%
Hold427%
Sell00%

Monthly trend

  1. Oct 202629415
  2. Sep 202618413
  3. Aug 202617412
  4. Jul 202617311

Counts of recommendations published by analysts covering Beta Bionics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
12.8%
of tradable shares
Days to cover
4.82
at average volume
Short interest, 1 month
−35%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.8%
of shares
Employees
420
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2026 to date
Return
BBNX−48%
Industry peers (median)−13%
S&P 500+11%
Months that ended higher
BBNX36%
S&P 50046%
Largest fall from a high during the year
BBNX−72%
S&P 500−9%

Worst fall since January 30, 2025: 72% from January 8, 2026 to April 10, 2026. Getting back needed a 261% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$8.86 – $31.99
From 52-week high
−50.3%
vs 50-day average
−16.5%
vs 200-day average
+7.4%
Volatility (1 year)
83%
Beta vs S&P 500
1.28

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 6 down
typical move ±14.8%
After a week
3 up, 5 down
typical move ±18.6%
After a month
4 up, 4 down
typical move ±35.4%
Results releasedNext dayS&P 500 next day5 days21 days
October 27, 2026 −13.0% +0.9% — —
July 29, 2026 −9.7% +0.1% −12.0% +23.7%
April 21, 2026 −5.5% +0.4% −21.9% −21.7%
February 17, 2026 −2.4% +0.7% −3.9% −23.7%
January 8, 2026 −36.0% +0.7% −43.5% −56.0%
October 28, 2025 +12.8% +0.3% +17.1% +29.9%
July 29, 2025 +19.8% −0.4% +13.0% +35.6%
May 6, 2025 +23.0% −0.4% +13.0% +67.4%
March 25, 2025 −11.4% −1.0% −24.3% −25.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Beta Bionics, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Beta Bionics, Inc.
$60M $80M $100M $120M $140M FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q3 Revenue (TTM), FY24 Q4: $65.1M Revenue (TTM), FY25 Q1: $69.8M Revenue (TTM), FY25 Q2: $78M Revenue (TTM), FY25 Q3: $88.6M Revenue (TTM), FY25 Q4: $100.3M Revenue (TTM), FY26 Q1: $110.2M Revenue (TTM), FY26 Q2: $119M Revenue (TTM), FY26 Q3: $127.3M $127.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q4 $65.1M
FY25 Q1 $69.8M
FY25 Q2 $78M
FY25 Q3 $88.6M
FY25 Q4 $100.3M
FY26 Q1 $110.2M
FY26 Q2 $119M
FY26 Q3 $127.3M
Revenue growth, TTM YoY Beta Bionics, Inc.
40% 45% 50% 55% 60% FY25 Q4 FY26 Q1 FY26 Q2 FY26 Q3 Revenue growth, TTM YoY, FY25 Q4: 53.9% Revenue growth, TTM YoY, FY26 Q1: 57.9% Revenue growth, TTM YoY, FY26 Q2: 52.5% Revenue growth, TTM YoY, FY26 Q3: 43.7% 43.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY25 Q4 53.9%
FY26 Q1 57.9%
FY26 Q2 52.5%
FY26 Q3 43.7%
Operating margin (TTM) Beta Bionics, Inc.
-100% -50% 0% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q3 Operating margin (TTM), FY24 Q4: -69.5% Operating margin (TTM), FY25 Q1: -78.0% Operating margin (TTM), FY25 Q2: -80.1% Operating margin (TTM), FY25 Q3: -77.4% Operating margin (TTM), FY25 Q4: -71.5% Operating margin (TTM), FY26 Q1: -70.1% Operating margin (TTM), FY26 Q2: -69.8% Operating margin (TTM), FY26 Q3: -72.7% -72.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q4 -69.5%
FY25 Q1 -78.0%
FY25 Q2 -80.1%
FY25 Q3 -77.4%
FY25 Q4 -71.5%
FY26 Q1 -70.1%
FY26 Q2 -69.8%
FY26 Q3 -72.7%
FCF margin (TTM) Beta Bionics, Inc.
-100% -50% 0% FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q3 FCF margin (TTM), FY24 Q4: -79.3% FCF margin (TTM), FY25 Q1: -85.1% FCF margin (TTM), FY25 Q2: -79.5% FCF margin (TTM), FY25 Q3: -68.3% FCF margin (TTM), FY25 Q4: -56.1% FCF margin (TTM), FY26 Q1: -55.4% FCF margin (TTM), FY26 Q2: -51.6% FCF margin (TTM), FY26 Q3: -51.8% -51.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q4 -79.3%
FY25 Q1 -85.1%
FY25 Q2 -79.5%
FY25 Q3 -68.3%
FY25 Q4 -56.1%
FY26 Q1 -55.4%
FY26 Q2 -51.6%
FY26 Q3 -51.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 12 65 100 127
Gross profit 6 36 56 75
EBITDA −35 −44 −70 −90
Operating income −36 −45 −72 −93
Net income −44 −55 −73 −83
Diluted EPS −$8.31 −$8.60 −$1.81 −$1.85
Growth (year on year)
Revenue — +442.9% +53.9% +43.7%
Margins
Gross margin 52.6% 55.1% 55.4% 58.6%
EBITDA margin −288.7% −67.7% −69.9% −70.6%
Operating margin −298.9% −69.5% −71.5% −72.7%
Net margin −367.6% −84.1% −73.0% −65.3%
Free-cash-flow margin −273.8% −79.3% −56.1% −51.8%
Cash flow
Cash from operations −32 −48 −51 −59
Capital spending 0 3 5 7
Free cash flow −33 −52 −56 −66
Stock-based pay 6 6 16 23
Free cash flow after stock pay −39 −58 −73 −89
Balance sheet
Cash 27 30 32 82
Total debt 0 0 0 0
Net debt (negative = net cash) −27 −30 −32 −82
Diluted shares 5m 6m 41m 45m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · September 30, 2026
What it owns · $444m
Short-term assets $293mLonger-term assets $151m
What it owes, and who funded it · $444m
Short-term liabilities $33mLonger-term liabilities $10mShareholders' equity $401m
  • Short-term assets cover short-term liabilities $293m of assets due within a year against $33m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $293m short-term assets against $10m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Beta Bionics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+44.6%
year over year
R&D spending
33.6%
of revenue
Days sales outstanding
59 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BBNX RXST ANIK OM OWLT INFU Median
Revenue, last 12 months $127m $128m $121m $118m $115m $143m $99m
Revenue growth, last 12 months 43.7% −13.2% 5.3% −1.3% 28.2% 2.5% 9.2%
Revenue growth, 3-year average — 23.9% 0.3% −3.1% 29.3% 6.6% 13.5%
Revenue growth, latest quarter 30.3% 0.3% 15.6% 0.7% 29.9% 2.6% 10.2%
Gross margin 58.6% 77.5% 62.2% 41.8% 54.8% 57.5% 61.2%
Operating margin −72.7% −43.2% −4.2% −56.1% −6.3% 9.3% −8.5%
Operating margin, 3-year average — −36.3% 0.2% −83.8% −17.9% 6.6% −17.9%
Net margin −65.3% −36.8% −3.1% −63.1% −7.7% 6.0% −12.0%
Cash from operations / revenue −46.6% −17.8% 5.0% −32.5% −6.8% 16.3% −1.9%
Free-cash-flow margin −51.8% −21.3% 0.5% −33.0% −7.4% 16.0% −3.9%
Free-cash-flow margin, 3-year average — −22.1% 0.4% −70.2% −14.1% 14.2% −7.0%
Stock pay / revenue 18.4% 24.6% 10.9% 13.0% 11.2% 3.5% 6.1%
Change in share count 44.6% 2.2% −4.0% 311.4% 72.6% −2.4% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 43.7% 9.1% 16 of 129
Change in growth rate Growth -8.8pp -0.6pp 107 of 129
Gross margin Profitability 58.6% 61.9% 71 of 123
Operating margin Profitability -72.7% -8.3% 96 of 132
Net margin Profitability -65.3% -12.0% 95 of 133
Free-cash-flow margin Cash generation -51.8% -3.4% 96 of 128
Stock pay as % of revenue Cash generation 18.4% 6.1% 96 of 123
Change in share count Balance sheet 44.6% 3.3% 104 of 115
Days sales outstanding Balance sheet 59 days 57 days 66 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$752M
Institutions reporting
132
Shares held vs prior quarter
▼ 2.7%
Positions opened / closed
26 / 23

Top buyers and sellers, Q2 2026: 81 institutions bought and 58 sold ; the biggest buyer was Divisadero Street Capital Management, LP (+1.1M shares) and the biggest seller Farallon Capital Management, L.L.C (−3.0M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Eventide Asset Management, LLC $98.1M 6.3M 13.0% ▲ 5.2%
Soleus Capital Management, L.P. $68.8M 4.4M 9.2% ▲ 0.9%
Morgan Stanley $66.9M 4.3M 8.9% ▲ 0.9%
Sands Capital Alternatives, LLC $58.1M 3.7M 7.7% 0.0%
Blackrock, Inc. $52.3M 3.3M 7.0% ▲ 9.9%
Point72 Asset Management, L.P. $35.3M 2.3M 4.7% ▼ 10.7%
Vanguard Capital Management LLC $27.9M 1.8M 3.7% ▲ 3.1%
Vestal Point Capital, LP $25.1M 1.6M 3.3% ▼ 27.7%
RTW Investments, LP $23.5M 1.5M 3.1% ▼ 25.0%
Deerfield Management Company, L.P. $20.7M 1.3M 2.8% 0.0%
Omega Fund Management, LLC $20.6M 1.3M 2.7% 0.0%
Eversept Partners, LP $19.6M 1.2M 2.6% ▼ 11.7%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Beta Bionics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5.4M 52 trades by 8 insiders · 73% under pre-set plans
Net ▼ $5.4M net selling
Insider Date Trade Shares Price Value
Mensinger Mike Chief Product Officer October 27, 2026 Sell pre-set plan 2,650 $22.00 $58,300
Hopman Mark Chief Commercial Officer October 26, 2026 Sell pre-set plan 821 $20.00 $16,420
Hopman Mark Chief Commercial Officer October 14, 2026 Sell pre-set plan 775 $17.35 $13,446
Hopman Mark Chief Commercial Officer October 1, 2026 Sell pre-set plan 370 $18.96 $7,015
Jones Christy Director September 22, 2026 Sell pre-set plan 6,430 $23.00 $147,890
Mensinger Mike Chief Product Officer September 16, 2026 Sell pre-set plan 2,650 $22.00 $58,300
Hopman Mark Chief Commercial Officer September 16, 2026 Sell pre-set plan 30,779 $20.13 $619,640
Hopman Mark Chief Commercial Officer September 14, 2026 Sell pre-set plan 775 $15.52 $12,028
Hopman Mark Chief Commercial Officer September 9, 2026 Sell pre-set plan 36,870 $18.46 $680,723
Hopman Mark Chief Commercial Officer September 9, 2026 Sell pre-set plan 35,994 $18.46 $664,550
Saint Sean President & CEO September 3, 2026 Sell pre-set plan 5,641 $20.08 $113,259
Saint Sean President & CEO September 2, 2026 Sell 16,867 $19.11 $322,381

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 13, 2027 estimated from the company's past filing pattern, not announced

  • October 27, 2026
  • July 29, 2026
  • April 21, 2026
  • February 17, 2026
  • January 8, 2026
  • October 28, 2025

Recent SEC filings

Data status

When each part of this page on Beta Bionics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Beta Bionics, Inc. in brief

What does Beta Bionics, Inc. do?
Beta Bionics, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Beta Bionics, Inc.'s stock ticker?
Beta Bionics, Inc. trades under the ticker BBNX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Beta Bionics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Beta Bionics, Inc. reported revenue of $127M, 43.7% higher than a year earlier, according to its SEC filings.
What is Beta Bionics, Inc.'s free cash flow?
Beta Bionics, Inc.'s free-cash-flow margin is -51.8% of revenue over the trailing twelve months, ranking 96 of the 128 health care equipment companies we cover.
Who are Beta Bionics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Eventide Asset Management, LLC, Soleus Capital Management, L.P. and Morgan Stanley. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Beta Bionics, Inc.'s market cap?
On November 2, 2026, Beta Bionics, Inc.'s market capitalisation was about $715M and net debt of -$81.6M. Market figures come from third-party market data and may be delayed.
Who are Beta Bionics, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Beta Bionics, Inc. are Rxsight, Inc., Anika Therapeutics, Inc., Outset Medical, Inc., Owlet, Inc. and Infusystem Holdings, Inc. The side-by-side comparison below sets their revenue, margins and growth against Beta Bionics, Inc.'s.
Are insiders buying or selling Beta Bionics, Inc. stock?
Over the last 12 months, Beta Bionics, Inc.'s directors and officers reported 0 open-market purchases and 52 sales on Form 4. The insider trading page charts every trade.
When is Beta Bionics, Inc.'s next earnings date?
Around January 13, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Beta Bionics, Inc. announces its own schedule.